Breaking News Instant updates and real-time market news.

GLPG

Galapagos NV

$90.83

-0.66 (-0.72%)

17:01
11/19/17
11/19
17:01
11/19/17
17:01

Galapagos NV reports positive topline results from ALBATROSS with GLPG2222

Galapagos NV reports positive topline results from its ALBATROSS Phase 2 study in cystic fibrosis patients with C1 corrector GLPG2222. The ALBATROSS study included 37 cystic fibrosis patients with a gating mutation on one allele and F508del mutation on the other allele. All patients were on long-term stable Kalydeco treatment at screening and continued their Kalydeco treatment throughout the study. The ALBATROSS study was fully recruited within five months. Primary objectives of this randomized, double-blinded, placebo controlled study were to evaluate the safety and tolerability and pharmacokinetics of novel C1 corrector GLPG2222 in this CF patient population. Once daily doses of 150mg GLPG2222, 300mg GLPG2222 or placebo were administered. Overall, GLPG2222 was well tolerated, with observed treatment emergent adverse events being predominantly mild or moderate, and typical for a CF patient population. There were no serious adverse events reported and no discontinuations due to adverse events. The targeted exposures of GLPG2222 were achieved in this patient study, further strengthening dosing modelling for the first investigational triple combination. Exposures achieved in patients were in line with those observed in healthy volunteers. The additional activity observed with treatment with GLPG2222 on top of Kalydeco was in line with what was observed with tezacaftor combined with Kalydeco in a Phase 2 study in this population. A statistically significant dose dependent decrease in sweat chloride concentration was observed amounting to a decrease of 6 mmol/L in the 300mg cohort. Mean percent predicted FEV1 levels overall were 70% at screening. At the end of treatment with 300mg GLPG2222, ppFEV1 levels increased by 2.2%.

GLPG Galapagos NV
$90.83

-0.66 (-0.72%)

09/15/17
STFL
09/15/17
NO CHANGE
Target $120
STFL
Buy
Galapagos NV price target raised to $120 from $101 at Stifel
After hosting a call with two key opinion leaders on idiopathic pulmonary fibrosis, Stifel analyst Adam Walsh noted that the physicians expressed the view that the efficacy of GLPG1690 in the Phase 2 FLORA trial "was as good as one could have hoped for." As a result of the positive physician feedback, he increased his probability of success for '1690 to 15% from 10% and raised his price target on Galapagos to $120 from $101. Walsh keeps a Buy rating on Galapagos shares.
09/14/17
RBCM
09/14/17
INITIATION
Target $98
RBCM
Sector Perform
Galapagos NV initiated with a Sector Perform at RBC Capital
RBC Capital analyst Brian Abrahams started Galapagos NV with a Sector Perform rating and $98 price target.
08/14/17
JEFF
08/14/17
NO CHANGE
JEFF
Buy
Expert IPF call positive for FibroGen, says Jefferies
Jefferies analyst Michael Yee says his call with two idiopathic pulmonary fibrosis experts was net positive for FibroGen (FGEN). Based on the available data, the experts estimated a 30%-40%-plus probability of success in Phase 3 for the company. The experts were "more conservative in the interpretation" of the data reported by Galapagos NV (GLPG), Yee tells investors in a research note. He reiterates a Buy rating on FibroGen given the "underappreciated value" for FG-3019 in IPF.
08/11/17
STFL
08/11/17
UPGRADE
Target $101
STFL
Buy
Stifel upgrades Galapagos with $101 target on 'clearly positive' data
Stifel analyst Adam Walsh upgraded Galapagos NV to Buy from Hold and raised his price target for the shares to $101 from $83. The stock closed yesterday up 11%, or $7.89, to $81.06. The early Phase 2 results for wholly-owned GLPG1690 in idiopathic pulmonary fibrosis were "clearly positive," Walsh tells investors in a research note. The analyst included the drug in his model with a "very reasonable" 10% probability of success. Further, he sees "reduced downside risk" associated with Galapagos' cystic fibrosis triple combo.

TODAY'S FREE FLY STORIES

WEN

Wendy's

$15.63

0.24 (1.56%)

, MCD

McDonald's

$173.35

-0.2 (-0.12%)

15:41
12/14/17
12/14
15:41
12/14/17
15:41
Hot Stocks
Chanos says he'd short almost all fast food stocks, except McDonald's »

While being interviewed…

WEN

Wendy's

$15.63

0.24 (1.56%)

MCD

McDonald's

$173.35

-0.2 (-0.12%)

QSR

Restaurant Brands

$61.49

0.16 (0.26%)

YUM

Yum! Brands

$82.12

-0.07 (-0.09%)

JACK

Jack in the Box

$102.49

-0.09 (-0.09%)

SONC

Sonic

$28.32

0.38 (1.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jan

  • 08

    Jan

  • 08

    Jan

SLM

Sallie Mae

$11.16

-0.45 (-3.88%)

15:40
12/14/17
12/14
15:40
12/14/17
15:40
Options
Sallie Mae sees notable call buying »

Sallie Mae sees notable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYL

Mylan

$39.53

0.24 (0.61%)

, PRGO

Perrigo

$82.91

-3.11 (-3.62%)

15:36
12/14/17
12/14
15:36
12/14/17
15:36
Periodicals
Mylan, Perrigo among those interesed in Merck KGaA unit, Bloomberg says »

Mylan (MYL), Perrigo…

MYL

Mylan

$39.53

0.24 (0.61%)

PRGO

Perrigo

$82.91

-3.11 (-3.62%)

MKGAY

Merck KGaA

RBGLY

Reckitt Benckiser

$18.17

0.11 (0.61%)

NSRGY

Nestle

$86.67

0.61 (0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EADSY

Airbus

$26.16

0.62 (2.43%)

15:34
12/14/17
12/14
15:34
12/14/17
15:34
Periodicals
Airbus COO expected to step down, Reuters reports »

Airbus COO and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JBL

Jabil Circuit

$27.56

-0.99 (-3.47%)

15:34
12/14/17
12/14
15:34
12/14/17
15:34
Options
Jabil Circuit options imply 8.5% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 09

    Jan

MCD

McDonald's

$173.34

-0.21 (-0.12%)

, QSR

Restaurant Brands

$61.42

0.09 (0.15%)

15:32
12/14/17
12/14
15:32
12/14/17
15:32
Hot Stocks
Jim Chanos says not short McDonald's, but is short other fast food stocks »

Chanos, in making…

MCD

McDonald's

$173.34

-0.21 (-0.12%)

QSR

Restaurant Brands

$61.42

0.09 (0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXPR

Express

$10.30

-0.66 (-6.02%)

15:30
12/14/17
12/14
15:30
12/14/17
15:30
Options
Express calls active as shares see relative weakness »

Express calls active as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jan

FOXA

21st Century Fox

$32.75

-1.35 (-3.96%)

, DIS

Disney

$111.17

3.555 (3.30%)

15:29
12/14/17
12/14
15:29
12/14/17
15:29
Recommendations
21st Century Fox, Disney analyst commentary  »

21st Century Fox should…

FOXA

21st Century Fox

$32.75

-1.35 (-3.96%)

DIS

Disney

$111.17

3.555 (3.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 14

    Dec

  • 15

    Dec

TSLA

Tesla

$339.03

-2 (-0.59%)

15:28
12/14/17
12/14
15:28
12/14/17
15:28
Hot Stocks
Tesla 'already behind' on vehicle autonomy, Chanos says »

Jim Chanos of Kynikos…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

TSLA

Tesla

$339.03

-2 (-0.59%)

15:27
12/14/17
12/14
15:27
12/14/17
15:27
Hot Stocks
Chanos says Tesla CEO Musk 'has broad interpretation of truth' »

Jim Chanos, who is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

BTC

Bitcoin

, BITCOIN

Bitcoin

15:19
12/14/17
12/14
15:19
12/14/17
15:19
General news
Chanos says 'not short' bitcoin but 'speculation' in it indicative of market »

Jim Chanos of Kynikos…

BTC

Bitcoin

BITCOIN

Bitcoin

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$176.83

4.29 (2.49%)

15:19
12/14/17
12/14
15:19
12/14/17
15:19
Options
Adobe options imply 6.2% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

EADSY

Airbus

$26.16

0.62 (2.43%)

15:17
12/14/17
12/14
15:17
12/14/17
15:17
Periodicals
Breaking Periodicals news story on Airbus »

Airbus CEO intends to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

15:17
12/14/17
12/14
15:17
12/14/17
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNK

Mallinckrodt

$23.11

-0.75 (-3.14%)

, ESRX

Express Scripts

$68.57

0.01 (0.01%)

15:16
12/14/17
12/14
15:16
12/14/17
15:16
Periodicals
Chanos says tax bill will affect healthcare more than people think »

Chanos mentioned…

MNK

Mallinckrodt

$23.11

-0.75 (-3.14%)

ESRX

Express Scripts

$68.57

0.01 (0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 14

    Dec

$NYE

NYSE Market Internals

15:16
12/14/17
12/14
15:16
12/14/17
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

, SPY

SPDR S&P 500 ETF Trust

$266.05

-0.705 (-0.26%)

15:12
12/14/17
12/14
15:12
12/14/17
15:12
Periodicals
Speaker Ryan says not leaving Congress anytime soon, CBS News reports »

Following a media report…

SPX

S&P 500

SPY

SPDR S&P 500 ETF Trust

$266.05

-0.705 (-0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JCP

J.C. Penney

$2.93

-0.095 (-3.15%)

15:10
12/14/17
12/14
15:10
12/14/17
15:10
Options
Bulls and bears in JC Penney Thursday »

Bulls and bears in JC…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMCSA

Comcast

$38.58

-0.93 (-2.35%)

, CMCSK

Comcast

15:06
12/14/17
12/14
15:06
12/14/17
15:06
Periodicals
Comcast offered more for Fox assets, but Fox preffered Disney deal, CNBC says »

Sources tell CNBC's…

CMCSA

Comcast

$38.58

-0.93 (-2.35%)

CMCSK

Comcast

FOXA

21st Century Fox

$32.75

-1.35 (-3.96%)

FOX

21st Century Fox

$32.34

-1.26 (-3.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 15

    Dec

COST

Costco

$188.28

-0.02 (-0.01%)

15:04
12/14/17
12/14
15:04
12/14/17
15:04
Options
Costco options imply 5.2% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

VRX

Valeant

$19.22

-2.83 (-12.83%)

15:03
12/14/17
12/14
15:03
12/14/17
15:03
Technical Analysis
Technical View: Valeant near session lows, levels to watch »

The shares are bouncing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 27

    Dec

  • 18

    Jun

CI

Cigna

$204.17

-3.75 (-1.80%)

15:02
12/14/17
12/14
15:02
12/14/17
15:02
Hot Stocks
Cigna announces acquisition of digital health plan platform Brighter »

Cigna announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:00
12/14/17
12/14
15:00
12/14/17
15:00
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

ORCL

Oracle

$50.25

0.195 (0.39%)

14:49
12/14/17
12/14
14:49
12/14/17
14:49
Options
Oracle options imply 7.2% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

DIS

Disney

$111.04

3.43 (3.19%)

, FOXA

21st Century Fox

$32.75

-1.35 (-3.96%)

14:44
12/14/17
12/14
14:44
12/14/17
14:44
Recommendations
Disney, 21st Century Fox analyst commentary  »

RBC Capital sees Disney,…

DIS

Disney

$111.04

3.43 (3.19%)

FOXA

21st Century Fox

$32.75

-1.35 (-3.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 14

    Dec

  • 15

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.